Articles tagged "Antibodies"

2020 American Transplant Congress
ABO Self-Tolerance in a Mouse Model: Evidence of Tolerance at B Cell but Not T Cell Level
I. Adam, B. Motyka, K. Tao, L. West
Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada
*Purpose: We showed that human infants become tolerant to donor A/B-antigens (Ag) after ABO-incompatible heart transplantation (ABOi-HTx) by mechanisms not well-defined. To expand ABOi-HTx effectively…
2020 American Transplant Congress
In-Vivo Application of Ides (Imlifidase) in Nonhuman Primates Results in Xenoreactive Desensitization: A Novel Anti-Humoral Therapy
B. P. Lovasik¹, A. J. Matar¹, D. A. Faber¹, D. V. Mathews¹, C. Breeden¹, S. C. Kim¹, A. J. Tector², A. Robertson³, C. Kjellman³, A. B. Adams¹
¹Emory University School of Medicine, Atlanta, GA, ²University of Miami, Miami, FL, ³HANSA Biopharma, Lund, Sweden
*Purpose: Antibody-mediated rejection is a formidable barrier to xenograft survival. A novel anti-humoral IdeS therapy, which cleaves serum IgG, represents a promising therapy to reduce…
2020 American Transplant Congress
Peak DSA Levels Pre-Transplant but Not at Transplant Predict Graft Survival
A. Y. Choi¹, D. Olaso¹, T. Risoli Jr², M. Kuchibhatla², Z. Fitch³, R. Schmitz³, P. M. Schroder³, A. Jackson³, M. Manook³, J. Yoon³, A. B. Farris⁴, J. Kwun³, S. J. Knechtle³
¹Duke University School of Medicine, Durham, NC, ²Duke Biostatistics, Epidemiology, and Research Design Core, Duke University, Durham, NC, ³Department of Surgery, Duke University Medical Center, Durham, NC, ⁴Department of Pathology, Emory University Hospital, Atlanta, GA
*Purpose: Immunization to major histocompatibility complex (MHC) antigens is a barrier in kidney transplantation (KTx) due to higher risk of antibody-mediated rejection (AMR) and graft…
2020 American Transplant Congress
Dominant Negative Polymorphisms in TNFRSF13B are Associated with Poor Transplant Outcome
M. G. de Mattos-Barbosa¹, E. T. Luning Prak², E. Farkash³, J. L. Platt⁴, M. Cascalho⁴
¹Transplant Surgery, University of Michigan, Ann Arbor, MI, ²Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Pathology, University of Michigan, Ann Arbor, MI, ⁴Transplant Surgery and Microbiology and Immunology, University of Michigan, Ann Arbor, MI
*Purpose: Transmembrane Activator and CAML Interactor (TACI) is a highly polymorphic receptor that controls B cell activation and differentiation into antibody-secreting cells. Allelic variants of…
2020 American Transplant Congress
Association between Longer Hospitalization and Development of De Novo Donor Specific Antibody in Simultaneous Liver-Kidney Transplant Recipients
M. Yazawa¹, O. Cseprekal², R. A. Helmick¹, M. Talwar¹, V. Balaraman¹, P. S. Podila³, S. Fossey⁴, S. K. Satapathy⁵, J. D. Eason¹, M. Z. Molnar¹
¹James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN, ²Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary, ³Faith & Health Division, Methodist Le Bonheur Healthcare, Memphis, TN, ⁴Transplant Immunology Laboratory, DCI Inc., Nashville, TN, ⁵Sandra Atlas Bass Center for Liver Diseases & Transplantation, Northshore University Hospital/Northwell Health, Manhasset, NY
*Purpose: De novo Donor Specific Antibodies (DSA) are considered a risk factor for worsening kidney allograft outcomes in recipients after simultaneous liver-kidney transplantation (SLK). No…
2020 American Transplant Congress
Profiling Non-HLA Antibodies in Antibody-Mediated Rejection Following Cardiac Transplantation
S. B. See¹, B. S. Mantell², K. J. Clerkin³, B. Ray⁴, E. R. Vasilescu⁵, C. Marboe⁵, Y. Naka⁶, S. Restaino³, P. C. Colombo³, L. Addonizio², M. A. Farr³, E. Zorn¹
¹Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY, ²Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, ³Department of Medicine, Columbia University Irving Medical Center, New York, NY, ⁴Research and Development, Immucor, Waukesha, WI, ⁵Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, ⁶Department of Surgery, Columbia University Irving Medical Center, New York, NY
*Purpose: Antibody-mediated rejection (AMR) driven by the development of donor-specific antibodies (DSA) directed against mismatched donor HLA is a major risk factor for graft loss…
2020 American Transplant Congress
Conversion to a Belatacept Based Immunosuppression Regimen in Renal Transplant Recipients
K. Paplaczyk, K. Cunningham, C. D'Agostino, D. Pinelli, J. Schulte, A. Shetty
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Belatacept, a co-stimulation blocker, is an alternative anti-rejection agent that may avoid nephrotoxic or intolerable adverse effects of calcineurin inhibitor (CNI) or mammalian target…
2020 American Transplant Congress
Eplet Mismatch Not Correlated with Antibody Mediated Rejection or Allograft Loss Among Kidney Transplant Recipients with De Novo Donor Specific Antibody
A. Basu¹, W. Jiqiu², A. Bentall², M. Gandhi², B. Dukek², N. Henderson², C. Schinstock²
¹Emory Healthcare, Atlanta, GA, ²Mayo Clinic, Rochester, MN
*Purpose: Eplet mismatches are associated with development of de novo DSA (dnDSA) in kidney transplant recipients. However, it remains unclear how the degree of eplet…
2020 American Transplant Congress
Lateral Flow Assay to Detect Soluble CD25 after Kidney Transplantation
L. K. Seiler, C. Blume, R. Jonczyk
Faculty of Natural Sciences, Institute of Technical Chemistry, Hannover, Germany
*Purpose: Kidney transplantations are one of the most common transplantations in the world; 80.696 kidneys were transplanted in 2017. Despite tremendous improvements in quality and…
2020 American Transplant Congress
What is the Significance of Denovo Donor Specific Antibodies in Recipients of Simultaneous Liver-Kidney Transplants?
S. Parajuli, F. Aziz, J. Blazel, B. Muth, N. Garg, M. Mohamed, J. Rice, J. Mezrich, L. Hidalgo, D. Mandelbrot, G. Im, B. Lee
University of Wisconsin, Madison, WI
*Purpose: There is limited information about the utility of donor-specific HLA antibody (DSA) testing and the role of protocol kidney biopsy for de-novo donor-specific antibodies…